Prevention of Traveler's Diarrhea

Sponsor
University of Palermo (Other)
Overall Status
Completed
CT.gov ID
NCT06125626
Collaborator
(none)
3
1
2
3
1

Study Details

Study Description

Brief Summary

The prevention of traveller's diarrhea makes use of the selection of foods and drinks, the purification of water, the use of pharmacological substances such as bismuth salicylate and rifaximin (which can only be taken for short periods). The very attractive prospect of preventing travellers' diarrhea without systemic antibiotics has fueled interest in probiotics for this purpose. However, not all probiotics are identical, and the results of studies conducted with a particular agent cannot be generalized to indicate that any probiotic agent would be successful in the same clinical situation. Probiotics such as Lactobacillus GG have been shown to reduce the incidence of diarrhea in travelers in randomized controlled trials. In contrast, another Lactobacillus preparation, non-viable Lactobacillus acidophilus, showed no benefit over placebo in a randomized, double-blind, controlled trial of 174 travelers. The reasons for this are unclear, but could be related to the fact that the bacteria were not viable or a peculiarity of the strain selected for testing.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Probiotical
  • Other: Placebo
Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
3 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Prevention of Traveler's Diarrhea While Crossing the Amazon Forest by Bike With a Supplement Based on Lacticaseibacillus Rhamnosus LR04 + Streptococcus Thermophilus FP4 + Bifidobacterium Brevis BR03: a Phase Two, Randomized, Placebo-controlled, Double-blind, Cross-over Pilot Study
Actual Study Start Date :
Jul 10, 2023
Actual Primary Completion Date :
Oct 7, 2023
Actual Study Completion Date :
Oct 10, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Probiotics

This arm will receive a daily sachet of Lacticaseibacillus rhamnosus LR04 + Streptococcus thermophilus FP4 + Bifidobacterium breve BR03

Dietary Supplement: Probiotical
A daily sachet of Lacticaseibacillus rhamnosus LR04 + Streptococcus thermophilus FP4 + Bifidobacterium breve BR03 will be given to this group

Placebo Comparator: Placebo

This arm will receive a dose of placebo

Other: Placebo
A daily sachet of placebo will be given to this groups

Outcome Measures

Primary Outcome Measures

  1. Incidence of diarrhea [12 weeks]

    Diarrhea will be defined using the Bristol's scale (value of 7) in a scale between 1 and 7, higher values reflecting more diarrhoic attitude

Secondary Outcome Measures

  1. Mean quality of life [12 weeks]

    Quality of life will be assessed using the short-form 12 (SF-12) with a standardized score between 0 and 100% compared to the Italian population.

  2. Incidence of severe diarrhea [12 weeks]

    Severe diarrhea will be defined as a diarrhea requiring hospitalization or intravenous hydratation

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy bikers

  • Able to pass the Amazonia forest by bike

Exclusion Criteria:
  • None predifinied

Contacts and Locations

Locations

Site City State Country Postal Code
1 Nicola Veronese Palermo Italy 90127

Sponsors and Collaborators

  • University of Palermo

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Nicola Veronese, Professor, University of Palermo
ClinicalTrials.gov Identifier:
NCT06125626
Other Study ID Numbers:
  • 153/2023
First Posted:
Nov 9, 2023
Last Update Posted:
Nov 13, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 13, 2023